Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diagnostic accuracy and added value of dynamic chest radiography in detecting pulmonary embolism: A retrospective study.
Yamasaki Y, Hosokawa K, Kamitani T, Abe K, Sagiyama K, Hino T, Ikeda M, Nishimura S, Toyoda H, Moriyama S, Kawakubo M, Matsutani N, Yabuuchi H, Ishigami K. Yamasaki Y, et al. Among authors: toyoda h. Eur J Radiol Open. 2024 Oct 5;13:100602. doi: 10.1016/j.ejro.2024.100602. eCollection 2024 Dec. Eur J Radiol Open. 2024. PMID: 39430407 Free PMC article.
Correction to: Artificial intelligence-assisted volume isotropic simultaneous interleaved bright- and black-blood examination for brain metastases.
Kikuchi K, Togao O, Kikuchi Y, Yamashita K, Momosaka D, Fukasawa K, Nishimura S, Toyoda H, Obara M, Hiwatashi A, Ishigami K. Kikuchi K, et al. Among authors: toyoda h. Neuroradiology. 2025 Jan 21. doi: 10.1007/s00234-024-03522-9. Online ahead of print. Neuroradiology. 2025. PMID: 39836233 No abstract available.
The current status of tumor markers as biomarkers in the era of immunotherapy for hepatocellular carcinoma: alpha-fetoprotein alone is not sufficient.
Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, Ohama H, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Toyoda H, Matono T, Yata Y, Ogawa C, Naganuma A, Tani J, Atsukawa M, Nishimura T, Tajiri K, Kawata K, Kosaka H, Kuroda H, Hirooka M, Nishikawa H, Tada F, Nakamura S, Kanayama Y, Nouso K, Tanaka H, Tanaka K, Imai M, Tsutsui A, Nagano T, Aoki T, Koshiyama Y, Morishita A, Itokawa N, Okubo T, Arai T, Fukunishi S, Noritake H, Nakamura Y, Yoshida O, Enomoto H, Kaibori M, Hiasa Y, Kumada T. Hiraoka A, et al. Among authors: toyoda h. Oncology. 2025 Feb 3:1-23. doi: 10.1159/000543405. Online ahead of print. Oncology. 2025. PMID: 39900019
Impact of Antiplatelet Medication Continuation on Surgical Outcomes after Minimally Invasive Posterior Lumbar Decompression Surgery: Retrospective Cohort Study.
Sawada Y, Tamai K, Toyoda H, Kato M, Suzuki A, Takahashi S, Iwamae M, Okamura Y, Kobayashi Y, Nakamura H, Terai H. Sawada Y, et al. Among authors: toyoda h. Global Spine J. 2025 Jan 29:21925682251318266. doi: 10.1177/21925682251318266. Online ahead of print. Global Spine J. 2025. PMID: 39879664 Free PMC article.
Structure-guided discovery of viral proteins that inhibit host immunity.
Yirmiya E, Hobbs SJ, Leavitt A, Osterman I, Avraham C, Hochhauser D, Madhala B, Skovorodka M, Tan JMJ, Toyoda HC, Chebotar I, Itkin M, Malitsky S, Amitai G, Kranzusch PJ, Sorek R. Yirmiya E, et al. Among authors: toyoda hc. Cell. 2025 Jan 20:S0092-8674(24)01478-8. doi: 10.1016/j.cell.2024.12.035. Online ahead of print. Cell. 2025. PMID: 39855193
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Matono T, et al. Among authors: toyoda h. J Gastroenterol Hepatol. 2025 Jan 22. doi: 10.1111/jgh.16884. Online ahead of print. J Gastroenterol Hepatol. 2025. PMID: 39844393
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Naganuma A, et al. Among authors: toyoda h. Cancer Med. 2025 Jan;14(2):e70618. doi: 10.1002/cam4.70618. Cancer Med. 2025. PMID: 39840727 Free PMC article.
Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors.
Yasuda T, Ito T, Ishikawa T, Mizuno K, Yamamoto T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Koshiyama Y, Yasuda S, Toyoda H, Ando Y, Shimoyama Y, Kawashima H. Yasuda T, et al. Among authors: toyoda h. Dig Liver Dis. 2025 Jan 18:S1590-8658(25)00038-6. doi: 10.1016/j.dld.2025.01.037. Online ahead of print. Dig Liver Dis. 2025. PMID: 39828442
Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction-Associated Steatotic Liver Disease.
Inukai Y, Ito T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Shimizu T, Hattori M, Takeyama T, Ando Y, Nishikawa T, Morita K, Toyoda H, Ishigami M, Kawashima H. Inukai Y, et al. Among authors: toyoda h. J Dig Dis. 2025 Jan 13. doi: 10.1111/1751-2980.13325. Online ahead of print. J Dig Dis. 2025. PMID: 39805320
1,510 results